Who
Peter E. Boyd
Chief People Officer
Company insider
Files Form 4 as: Chief People Officer, Aquestive Therapeutics.
In numbers
- Trades disclosed
- 40
- Buys
- 5
- Sells
- 4
- Bought
- $14K
- Sold
- $461K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 24 Jul 2018
- Last trade
- 9 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Sep 2026filed 10 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code X | $2,2012,293 at $0.96 | filing |
| 9 Sep 2026filed 10 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code X | —2,293 at $0.00 | filing |
| 9 Sep 2026filed 10 Sep 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code X | —2,293 at $0.00 | filing |
| 9 Sep 2026filed 10 Sep 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code X | $2,2012,293 at $0.96 | filing |
| 5 May 2026filed 7 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $237K56,778 at $4.18 | filing |
| 5 May 2026filed 7 May 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $237K56,778 at $4.18 | filing |
| 10 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $124K29,814 at $4.17 | filing |
| 10 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $124K29,814 at $4.17 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $182K42,500 at $4.29 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $182K42,500 at $4.29 | filing |
| 9 Mar 2026filed 11 Mar 2026 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 4 Dec 2025filed 5 Dec 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 15 Oct 2025filed 17 Oct 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $70K10,000 at $7.00 | filing |
| 26 Sep 2025filed 29 Sep 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $63K10,000 at $6.30 | filing |
| 5 Sep 2025filed 8 Sep 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $80K15,000 at $5.30 | filing |
| 9 Mar 2025filed 11 Mar 2025 | AQST Aquestive TherapeuticsPharmaceuticals | SEC FORM 4 Code F | $20K7,681 at $2.65 | filing |
| 7 Mar 2025filed 13 Apr 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 7 Mar 2025filed 13 Apr 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Aquestive Therapeutics Wins FDA Acceptance Of Anaphylm NDA ResubmissionAQST · rttnews.com · 15 Oct 2026Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmAQST · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Peter E. Boyd; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.